On July 22, Baheal Pharma Group signed a significant strategic partnership agreement with ZAP Surgical, a global leader in radiosurgery robotics. The signing ceremony was attended by John R. Adler, Founder and CEO of ZAP Surgical, along with Fu Gang, Chairman of Baheal Pharma Group, and Song Qing, President of Baheal Pharma Group, as well as other representatives from both parties.

The partnership includes equity investment, large-scale production, and commercial operations of ZAP Surgical’s flagship product, the ZAP-X® radiosurgery robot. Baheal has previously made significant advances in the medical linear accelerator sector, investing in and developing China’s first X-band 4π intelligent robotic radiotherapy system. This collaboration with ZAP is expected to boost their international competitiveness in the precision radiotherapy arena.

In a speech, John Adler described himself as "Sometimes an Entrepreneur, Always a Doctor." This reflects his genuine commitment as a neurosurgeon to developing safer and more effective treatments to aid more patients. This aligns seamlessly with Baheal Pharma Group's mission to "optimize medical scenarios through technological innovation."

At the signing ceremony for the strategic partnership between Baheal Pharma Group and ZAP Surgical, Mr. Fu Gang is pictured on the left, and Dr. John R. Adler on the right.

The ZAP-X, the world's first shield-free radiosurgery robot, is a precise "scalpel" in the field of radiation therapy

The core principle of radiation therapy is to accurately target and kill tumor cells while protecting normal tissue from damage. Consequently, the focus of developing new radiotherapy equipment is on significantly improving the targeting efficiency of radiation, ensuring that it is maximally concentrated on tumor cells and minimizing potential harm to surrounding tissues.

ZAP is a leading global platform focused on the development of radiation therapy applications. Its founder and CEO, Dr. John R. Adler, is an Emeritus Professor of Neurosurgery and Radiation Oncology at Stanford University. Known worldwide for his technological innovations, Dr. Adler is the creator of the well-known CyberKnife system in the field of radiation therapy.

To further reduce the damage to normal brain tissue caused by radiation, Dr. Adler developed the ZAP-X® Gyroscopic Radiosurgery platform, a system specifically designed for the treatment of intracranial and cervical malignancies. This platform is the subject of the recent signing agreement and is the world’s first self-shielding radiation therapy device. Since its launch, it has garnered significant attention from medical institutions worldwide.

The ZAP-X device, as is shown in the picture.

The ZAP-X leverages a unique self-shielding design, ingeniously integrating the linear accelerator with the self-shielding radiation structure. This eliminates the need for traditional radiation shielding facilities that can cost millions. With simple expansions, ZAP-X can provide immediate radiation therapy services in outpatient offices, basic medical institutions, and even unconventional locations like train stations or conference rooms, significantly enhancing the accessibility of radiation therapy.

Resembling a large gyroscope, the ZAP-X features a spherical shielding structure housing two 45-degree rotatable circular tracks and a treatment table with three degrees of freedom. Together, they enable the device to offer over 260 radiation beam angles, facilitating non-coplanar radiotherapy with ease.

At its core, the ZAP-X utilizes an improved collimator to concentrate these beams precisely on the tumor target area. This enhances the therapeutic effect on the target while further reducing radiation doses to surrounding healthy tissues and shortening patient treatment times, making it akin to a sharp "surgical knife."

An additional notable advantage of the ZAP-X is its real-time image guidance and dose monitoring capabilities. It verifies the radiation dose and targeting position of each treatment beam with sub-millimeter precision. If any deviation in the radiation dose is detected, the system immediately halts operation, ensuring the non-invasive, safe, and effective nature of the treatment to the utmost extent.

The device was registered in the United States in September 2017. In 2018, ZAP-X received China's special approval procedure for innovative medical devices, and in 2019, it was installed for clinical trial research at the General Hospital of the People's Liberation Army. On June 20, 2023, the device was officially approved for marketing in China.

Expansion of High-End Medical Device Portfolio, Baheal Accelerates Innovation in Radiation Therapy Technology

High-end medical devices, symbolizing advanced manufacturing capabilities and cutting-edge technology, have become a key focus in global competition. "Scientific progress is a global and contemporary issue; open cooperation is the only right path."

At the National Conference on Science and Technology, the National Science and Technology Awards Conference, and the Academicians’ Conference of the Chinese Academy of Sciences and the Chinese Academy of Engineering held in June this year, it was emphasized, "We must deeply implement international scientific and technological cooperation initiatives, and broaden channels for government and private sector exchanges and cooperation," to ensure that technology better serves humanity.

In recent years, Baheal has actively responded to the national call to support private enterprises participating in scientific and technological innovation. Leveraging its innovative capabilities and industry insight in the healthcare sector, Baheal has actively collaborated with leading innovative forces both domestically and internationally.

As an "industry investor," Baheal leverages years of sector experience and clinical insight to identify "true innovations" that can optimize clinical scenarios. It allocates industry resources according to the varying growth stages of enterprises, providing support in aspects such as clinical research, patent applications, and regulatory submissions. From the launch of innovative products to their commercialization phases, Baheal also utilizes its industrial capabilities to assist in scaling up production and achieving market entry. This not only accelerates clinical adoption to benefit patients but also ensures that innovative achievements realize their commercial potential.

Currently, through the Baheal Zhongxin Industrial Fund, Baheal is focusing on three key value sectors: innovative drugs, high-end medical devices, and basic research platforms. The company seeks to discover and incubate truly groundbreaking innovations with technological barriers. In the high-end medical device sector, Baheal has already made significant progress in areas such as the fully magnetic levitation artificial heart, medical linear accelerators, nuclear medicine SPECT/CT, and electromagnetic navigation devices for ultrasound. Through its recent collaboration with ZAP, Baheal has further expanded its high-end medical device portfolio and will continue to contribute to the reform and innovation of China's medical device industry.